Neuraminidase Inhibitors Drug Market Size, Share, Growth, and Industry Analysis, By Types (Oseltamivir, Zanamivir, Peramivir, Laninamivir) , Applications (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) and Regional Insights and Forecast to 2033

Detailed TOC of Global Neuraminidase Inhibitors Drug Market Research Report 2025

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Oseltamivir
1.2.3 Zanamivir
1.2.4 Peramivir
1.2.5 Laninamivir
1.3 Market by Application
1.3.1 Global Neuraminidase Inhibitors Drug Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuraminidase Inhibitors Drug Market Perspective (2018-2033)
2.2 Neuraminidase Inhibitors Drug Growth Trends by Region
2.2.1 Global Neuraminidase Inhibitors Drug Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Neuraminidase Inhibitors Drug Historic Market Size by Region (2018-2025)
2.2.3 Neuraminidase Inhibitors Drug Forecasted Market Size by Region (2024-2033)
2.3 Neuraminidase Inhibitors Drug Market Dynamics
2.3.1 Neuraminidase Inhibitors Drug Industry Trends
2.3.2 Neuraminidase Inhibitors Drug Market Drivers
2.3.3 Neuraminidase Inhibitors Drug Market Challenges
2.3.4 Neuraminidase Inhibitors Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue
3.1.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue (2018-2025)
3.1.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2018-2025)
3.2 Global Neuraminidase Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neuraminidase Inhibitors Drug Revenue
3.4 Global Neuraminidase Inhibitors Drug Market Concentration Ratio
3.4.1 Global Neuraminidase Inhibitors Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuraminidase Inhibitors Drug Revenue in 2022
3.5 Neuraminidase Inhibitors Drug Key Players Head office and Area Served
3.6 Key Players Neuraminidase Inhibitors Drug Product Solution and Service
3.7 Date of Enter into Neuraminidase Inhibitors Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuraminidase Inhibitors Drug Breakdown Data by Type
4.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Type (2018-2025)
4.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2024-2033)
5 Neuraminidase Inhibitors Drug Breakdown Data by Application
5.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Application (2018-2025)
5.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Neuraminidase Inhibitors Drug Market Size (2018-2033)
6.2 North America Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Neuraminidase Inhibitors Drug Market Size by Country (2018-2025)
6.4 North America Neuraminidase Inhibitors Drug Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuraminidase Inhibitors Drug Market Size (2018-2033)
7.2 Europe Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Neuraminidase Inhibitors Drug Market Size by Country (2018-2025)
7.4 Europe Neuraminidase Inhibitors Drug Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size (2018-2033)
8.2 Asia-Pacific Neuraminidase Inhibitors Drug Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2018-2025)
8.4 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neuraminidase Inhibitors Drug Market Size (2018-2033)
9.2 Latin America Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Neuraminidase Inhibitors Drug Market Size by Country (2018-2025)
9.4 Latin America Neuraminidase Inhibitors Drug Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size (2018-2033)
10.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2018-2025)
10.4 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Neuraminidase Inhibitors Drug Introduction
11.1.4 Roche Revenue in Neuraminidase Inhibitors Drug Business (2018-2025)
11.1.5 Roche Recent Development
11.2 GSK
11.2.1 GSK Company Detail
11.2.2 GSK Business Overview
11.2.3 GSK Neuraminidase Inhibitors Drug Introduction
11.2.4 GSK Revenue in Neuraminidase Inhibitors Drug Business (2018-2025)
11.2.5 GSK Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Detail
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Neuraminidase Inhibitors Drug Introduction
11.3.4 Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2018-2025)
11.3.5 Gilead Sciences Recent Development
11.4 Daiichi Sankyo
11.4.1 Daiichi Sankyo Company Detail
11.4.2 Daiichi Sankyo Business Overview
11.4.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Introduction
11.4.4 Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2018-2025)
11.4.5 Daiichi Sankyo Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Neuraminidase Inhibitors Drug Introduction
11.5.4 AstraZeneca Revenue in Neuraminidase Inhibitors Drug Business (2018-2025)
11.5.5 AstraZeneca Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Neuraminidase Inhibitors Drug Introduction
11.6.4 Pfizer Revenue in Neuraminidase Inhibitors Drug Business (2018-2025)
11.6.5 Pfizer Recent Development
11.7 Teva
11.7.1 Teva Company Detail
11.7.2 Teva Business Overview
11.7.3 Teva Neuraminidase Inhibitors Drug Introduction
11.7.4 Teva Revenue in Neuraminidase Inhibitors Drug Business (2018-2025)
11.7.5 Teva Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Detail
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Introduction
11.8.4 Bristol-Myers Squibb Revenue in Neuraminidase Inhibitors Drug Business (2018-2025)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Sun Pharmaceutical
11.9.1 Sun Pharmaceutical Company Detail
11.9.2 Sun Pharmaceutical Business Overview
11.9.3 Sun Pharmaceutical Neuraminidase Inhibitors Drug Introduction
11.9.4 Sun Pharmaceutical Revenue in Neuraminidase Inhibitors Drug Business (2018-2025)
11.9.5 Sun Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details